Edition:
United Kingdom

Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application


Monday, 12 Feb 2018 

Feb 12 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING.